Brief: Abeona Therapeutics Announces Additional Phase 3 Viital Study Results For Eb-101 Presented At The International Societies For Investigative Dermatology 2023 Meeting
11/05/2023 13:39
May 11 (Reuters) - Abeona Therapeutics Inc ABEO.O :
* ABEONA THERAPEUTICS ANNOUNCES ADDITIONAL PHASE 3 VIITAL™
STUDY
RESULTS FOR EB-101 PRESENTED AT THE INTERNATIONAL SOCIETIES FOR
INVESTIGATIVE DERMATOLOGY 2023 MEETING
Source text for Eikon: ID:nGNX5h09mq
Further company coverage: ABEO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abeona Therapeutics
See all newsBrief: Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ultragenyx rises after FDA nod for rare disorder drug
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports